Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
The relentless pursuit of effective cancer treatments often hinges on understanding and targeting the unique metabolic pathways that cancer cells exploit for survival and proliferation. Glutamine metabolism, mediated by the enzyme glutaminase (GLS), is a critical node in this network. Inhibitors of GLS, such as CB-839, are therefore highly sought after as pharmaceutical intermediates for research and drug development. This article explores why CB-839 is a pivotal compound in advanced cancer research.
CB-839, characterized by its potent, selective, and non-competitive inhibition of glutaminase GLS1, offers a precise tool for investigating the role of glutaminolysis in cancer. As a pharmaceutical intermediate, it enables researchers to explore how targeting this pathway can disrupt cancer cell growth. Its chemical properties, including oral bioavailability, further enhance its utility in preclinical and potential clinical applications. The ability to precisely modulate glutamine metabolism makes CB-839 a cornerstone for innovative cancer therapies.
The scientific literature extensively documents the antiproliferative and antitumor activities of CB-839 across various cancer models, notably triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC). Its efficacy as a single agent and its synergistic potential when combined with established chemotherapies like Paclitaxel and Erlotinib highlight its versatility. These combination strategies aim to create a metabolic crisis within cancer cells, leading to enhanced cell death and improved treatment outcomes. This multifaceted activity makes CB-839 a critical component for advanced cancer research.
For researchers and pharmaceutical developers, reliable access to high-quality CB-839 is essential. NINGBO INNO PHARMCHEM CO.,LTD. is a dedicated supplier of this critical pharmaceutical intermediate, ensuring the scientific community has the tools necessary for groundbreaking discoveries. By providing pure and well-characterized CB-839, the company supports the advancement of cancer research and the development of next-generation therapies. Investing in CB-839 is investing in the future of cancer treatment.
In conclusion, CB-839's role as a pharmaceutical intermediate in advanced cancer research cannot be overstated. Its potent GLS1 inhibition, demonstrated preclinical efficacy, and synergistic potential make it a vital compound for uncovering new therapeutic strategies. NINGBO INNO PHARMCHEM CO.,LTD. is committed to supplying this essential research chemical, contributing to the global effort to combat cancer through metabolic intervention and targeted therapies.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
